The business model of Evogene Ltd revolves around leveraging advanced biotechnology to develop innovative agricultural solutions. Evogene specializes in computational biology, genomics, and predictive algorithms to accelerate seed and crop improvement processes. Through strategic collaborations with leading seed and agrochemical companies, Evogene aims to provide sustainable and high-performing crop traits that enhance productivity, yield, and quality. By utilizing its proprietary technologies, Evogene strives to address challenges faced by farmers and the agriculture industry, such as improving crop resilience, combating diseases, and increasing nutritional value. Evogene's business model focuses on applying cutting-edge science to drive agricultural innovation and create value for its customers.

Evogene Ltd is primarily active in the fields of agriculture and biotechnology.

The main competitors of Evogene Ltd in the market include companies such as Monsanto Company, Bayer AG, and Syngenta AG. These companies operate in the same biotechnology sector and compete with Evogene in various aspects, including agricultural research and development, genetically modified products, and crop protection solutions. Evogene Ltd faces competition from these major global players as they strive to capture a significant share of the market and deliver innovative solutions for sustainable agriculture.

Evogene Ltd is an Israeli biotechnology company focused on improving crop productivity and sustainability. Established in 2002, Evogene has developed advanced computational genomics technologies to enhance various traits in crops. By leveraging its proprietary computational biology platform, the company identifies and validates novel genes, leading to the development of improved seeds and agrochemical products. Evogene collaborates with leading seed companies and crop protection firms to bring innovative solutions to the market. With a strong emphasis on research and development, Evogene continues to drive advancements in the agricultural sector, aiming to address global food and environmental challenges through cutting-edge technology.

Evogene Ltd has achieved significant milestones in its journey. Over the years, the company has made remarkable progress and accomplishments. Some notable milestones include the successful development and commercialization of innovative agricultural traits and products. Evogene has also established important collaborations and partnerships with leading companies and organizations in the industry. Through its advanced computational biology and predictive biology capabilities, Evogene has consistently delivered cutting-edge solutions and technologies for enhancing crop productivity and agricultural sustainability. These achievements have solidified Evogene's position as a pioneering player in the field, driving growth and value creation for the company and its stakeholders.

Evogene Ltd is primarily present in Israel and has a significant presence in the United States as well.

Evogene Ltd represents values of innovation, sustainability, and collaboration. With a strong corporate philosophy, Evogene is committed to developing cutting-edge technologies in the fields of agroscience and crop improvement. By harnessing the power of computational biology and advanced genomic technologies, Evogene strives to address global challenges in food security and sustainable agriculture. The company focuses on partnerships and collaborations with leading industry players to drive the development and commercialization of its innovative solutions. Through its dedication to scientific excellence and a sustainable future, Evogene Ltd aims to revolutionize the agricultural industry and ensure a more productive and resilient food supply.

Analysts currently set an average price target of 2,55 USD for the Evogene stock (median: 2,55 USD), implying −95,7 % versus the latest price. The consensus is based on 7 analyst ratings.

Evogene Analyytikkojen kursstavoitteet 2026

7 analysts currently rate the Evogene stock: 6 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Evogene to generate revenue of 2,19 M USD and earnings per share of −2,11 USD.

Evogene Analyytikkojen kursstavoitteet 2026

Converted at the current exchange rate, the Evogene share trades at 51,64 EUR (59,45 USD).

The Evogene share (EVGN) is listed on 2 stock exchanges, including: NASDAQ (EVGN).

Evogene Ltd is a leading company in the agricultural biotechnology industry that specializes in discovering and developing new solutions for the challenges of global agriculture. The business model of Evogene is divided into various divisions that are closely interconnected and form the core of the company's operations. One important division is the genomics technology platform that Evogene uses to create models for plants that can increase their resistance to diseases, pests, and environmental stress. Another important area for Evogene is the development of new products for agriculture based on their genomics technology. Evogene collaborates with leading agricultural corporations to develop seeds and other plant products that are tailored to the specific needs of agriculture. One of Evogene's key products is the Insect Control Trait (ICT), which was developed based on RNA interference. ICT is a revolutionary method for controlling pests that allows targeting and elimination of specific genes in the insect's food system. The company also has a division dedicated to the development of fertilizers and other products aimed at increasing crop yield and quality results. Evogene works with universities and research institutions to develop new methods for soil optimization and plant nutrition. In addition to these various divisions, Evogene also has a strong focus on research and development to ensure constant innovation of the offered products and technologies. The company relies on close collaboration with its customers and partners to meet the specific needs of agriculture. In summary, Evogene's business model is geared towards providing sustainable and innovative solutions for the challenges of global agriculture. With its focus on genomics technology and close collaboration with customers and partners, Evogene is well positioned to continue growing and expanding in this field.

odotettu liikevaihto Evogene on 2,19 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Evogene on −12,01 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Evogene:n hinta-voitto-suhde (P/E) on tällä hetkellä −28,21. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Evogene-osakkeen arvostusta.

Evogene:n hinta-myynti-suhde (P/S) on tällä hetkellä 154,45. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Evogene-osakkeen arvostuskennuslukuna.

Evogene:n Eulpool-laatuscore on 3/10.

Evogene:n ISIN on IL0011050551. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Evogene:n WKN on A0Q7UP. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Evogene:n ticker on EVGN. Tämä pörssinoteeraus käytetään Evogene-osakkeiden kauppaan pörssissä.

Evogene maksoi osinkoa joka vuosi viimeisten 0 vuoden aikana.

Evogene kuuluu sektoriin 'Terveydenhuolto'.

Evogene:n osingot jaetaan valuutassa USD.